Clinical Trials & Research
Search Clinical Trials
|Title||A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia|
|Description||The primary purpose of this study is to evaluate the safety and tolerability of ONO-7746 across multiple doses in patients with solid tumors and chemotherapy induced thrombocytopenia (CIT) scheduled to receive at least two cycles of myelosuppressive chemotherapy on Day 1 every 21 days at the same dosages and schedule in the study. |
The secondary objectives are to characterize the PK profiles of ONO-7746 and to explore the pharmacodynamic effect of ONO-7746 on CIT.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be 18 Years and older
* Subject must have experienced thrombocytopenia as evidenced by a platelet count less than 100 Gi/L in the preceding cycle immediately before study enrollment.
|Principal Investigator||Sanjay Goel, MD|
|Current Trial Type||Interventional|